Transient Impact of Dysglycemia on Sputum Conversion among Smear-Positive Tuberculosis Patients in a Tertiary Care Facility in Ghana.
Tuberculosis
dysglycemia
smear Positive
sputum Conversion
transient.
Journal
Clinical medicine insights. Circulatory, respiratory and pulmonary medicine
ISSN: 1179-5484
Titre abrégé: Clin Med Insights Circ Respir Pulm Med
Pays: United States
ID NLM: 101537753
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
04
2021
accepted:
26
07
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Apart from increasing the risk of tuberculosis (TB), diabetes may be associated with more severe disease and lower rates of sputum conversion among TB patients. We conducted a baseline cross-sectional study with a longitudinal follow-up of newly diagnosed smear-positive TB patients for 6 months. Sputum conversion rates between those with dysglycemia and those without were compared at 2 months (end of the intensive phase) and 6 months (end of the treatment). Descriptive statistics and logistic regression were computed to assess factors associated with dysglycemia as well as sputum conversion. A significantly higher proportion of normoglycemic patients had negative sputum compared with those with dysglycemia (83% vs 67%, A significantly lower proportion of smear-positive TB patients with dysglycemia converted to smear negative after 2 months of treatment but not at the end of the treatment, thus suggesting a transient impact of dysglycemia on sputum conversion.
Sections du résumé
BACKGROUND
BACKGROUND
Apart from increasing the risk of tuberculosis (TB), diabetes may be associated with more severe disease and lower rates of sputum conversion among TB patients.
METHODS
METHODS
We conducted a baseline cross-sectional study with a longitudinal follow-up of newly diagnosed smear-positive TB patients for 6 months. Sputum conversion rates between those with dysglycemia and those without were compared at 2 months (end of the intensive phase) and 6 months (end of the treatment). Descriptive statistics and logistic regression were computed to assess factors associated with dysglycemia as well as sputum conversion.
RESULTS
RESULTS
A significantly higher proportion of normoglycemic patients had negative sputum compared with those with dysglycemia (83% vs 67%,
CONCLUSION
CONCLUSIONS
A significantly lower proportion of smear-positive TB patients with dysglycemia converted to smear negative after 2 months of treatment but not at the end of the treatment, thus suggesting a transient impact of dysglycemia on sputum conversion.
Identifiants
pubmed: 34566441
doi: 10.1177/11795484211039830
pii: 10.1177_11795484211039830
pmc: PMC8458672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11795484211039830Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Lancet Infect Dis. 2009 Dec;9(12):737-46
pubmed: 19926034
J Diabetes Metab Disord. 2012 Dec 20;11(1):28
pubmed: 23497638
Int J Tuberc Lung Dis. 2003 Jan;7(1):58-64
pubmed: 12701836
Chronic Illn. 2007 Sep;3(3):228-45
pubmed: 18083679
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
J Epidemiol Community Health. 2012 Jun;66(6):519-23
pubmed: 21109542
Kekkaku. 1992 Dec;67(12):755-60
pubmed: 1294780
Allergol Immunopathol (Madr). 2007 Jul-Aug;35(4):136-44
pubmed: 17663922
Clin Chem. 2002 Mar;48(3):436-72
pubmed: 11861436
Thorax. 2013 Mar;68(3):214-20
pubmed: 23250998
BMC Med. 2015 Jun 05;13:135
pubmed: 26048371
Pulm Med. 2013;2013:828939
pubmed: 23476764
Diabete Metab. 1992 May-Jun;18(3):187-201
pubmed: 1397473
East Mediterr Health J. 2003 Jul;9(4):689-701
pubmed: 15748066
Monaldi Arch Chest Dis. 1999 Aug;54(4):307-10
pubmed: 10546470
Infect Dis Poverty. 2013 Mar 27;2(1):6
pubmed: 24499664
Diabetes Care. 2012 Dec;35(12):2650-64
pubmed: 23100048
Kekkaku. 1990 Dec;65(12):791-803
pubmed: 2077255
Sci Rep. 2021 Jan 22;11(1):2113
pubmed: 33483542
Am J Trop Med Hyg. 2009 Apr;80(4):634-9
pubmed: 19346391
Epidemiol Infect. 2007 Apr;135(3):483-91
pubmed: 16863600
Clin Infect Dis. 2007 Aug 15;45(4):428-35
pubmed: 17638189
J Formos Med Assoc. 2011 Jun;110(6):372-81
pubmed: 21741005
Tubercle. 1990 Dec;71(4):271-6
pubmed: 2267680
Tubercle. 1990 Jun;71(2):135-8
pubmed: 2219464
Biomed Environ Sci. 2017 May;30(5):384-389
pubmed: 28549496
Epidemiol Rev. 2007;29:115-28
pubmed: 17494056
Trop Med Int Health. 2010 Nov;15(11):1300-14
pubmed: 20958887
Lancet Glob Health. 2019 Apr;7(4):e448-e460
pubmed: 30819531
PLoS One. 2015 Mar 30;10(3):e0121698
pubmed: 25822974
FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):259-65
pubmed: 10575137
Diabetes Care. 1992 Jul;15(7):912-4
pubmed: 1516514
J Womens Health (Larchmt). 2014 Feb;23(2):112-9
pubmed: 24206025
Int J Tuberc Lung Dis. 2006 Jan;10(1):74-9
pubmed: 16466041
BMC Med. 2011 Jul 01;9:81
pubmed: 21722362
Emerg Infect Dis. 2010 Oct;16(10):1546-53
pubmed: 20875279
Tuberc Res Treat. 2017;2017:1702578
pubmed: 29270319